SPL Medical of the Netherlands has signed an agreement with BE Imaging of Germany covering SPL's Combidex (ferumoxtran-10) MRI contrast agent. BE made an investment in SPL as part of the deal.
SPL was incorporated in August 2015 as a spin-off of Radboud University Nijmegen Medical Center in the Netherlands, with one of its lead products being Combidex, which is designed to detect cancer metastases as small as 2 mm in the lymph nodes. SPL hopes to begin the European regulatory registration process for Combidex in the beginning of 2017.
BE Imaging is part of the Bender Group in Baden-Baden, and has specialized in the distribution and marketing of products in radiology and urology, including generic contrast media, in Germany, Austria, and Switzerland. The company already distributes LumiVision, an oral MRI contrast product for MR cholangiopancreatography (MRCP).
